188 related articles for article (PubMed ID: 23514635)
1. Use of azathioprine and the risk of cancer in inflammatory bowel disease.
Pasternak B; Svanström H; Schmiegelow K; Jess T; Hviid A
Am J Epidemiol; 2013 Jun; 177(11):1296-305. PubMed ID: 23514635
[TBL] [Abstract][Full Text] [Related]
2. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
3. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
[TBL] [Abstract][Full Text] [Related]
4. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study.
Armstrong RG; West J; Card TR
Am J Gastroenterol; 2010 Jul; 105(7):1604-9. PubMed ID: 20104215
[TBL] [Abstract][Full Text] [Related]
5. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease.
Nyboe Andersen N; Pasternak B; Basit S; Andersson M; Svanström H; Caspersen S; Munkholm P; Hviid A; Jess T
JAMA; 2014 Jun; 311(23):2406-13. PubMed ID: 24938563
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study.
Munk EM; Pedersen L; Floyd A; Nørgård B; Rasmussen HH; Sørensen HT
Am J Gastroenterol; 2004 May; 99(5):884-8. PubMed ID: 15128355
[TBL] [Abstract][Full Text] [Related]
7. Risk of acute pancreatitis in users of azathioprine: a population-based case-control study.
Floyd A; Pedersen L; Nielsen GL; Thorlacius-Ussing O; Sorensen HT
Am J Gastroenterol; 2003 Jun; 98(6):1305-8. PubMed ID: 12818274
[TBL] [Abstract][Full Text] [Related]
8. Association between use of azathioprine and risk of acute pancreatitis in children with inflammatory bowel disease: a Swedish-Danish nationwide cohort study.
Wintzell V; Svanström H; Olén O; Melbye M; Ludvigsson JF; Pasternak B
Lancet Child Adolesc Health; 2019 Mar; 3(3):158-165. PubMed ID: 30685366
[TBL] [Abstract][Full Text] [Related]
9. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine.
Vernier-Massouille G; Cosnes J; Lemann M; Marteau P; Reinisch W; Laharie D; Cadiot G; Bouhnik Y; De Vos M; Boureille A; Duclos B; Seksik P; Mary JY; Colombel JF
Gut; 2007 Oct; 56(10):1404-9. PubMed ID: 17504943
[TBL] [Abstract][Full Text] [Related]
10. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
[TBL] [Abstract][Full Text] [Related]
11. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease.
Lopez A; Mounier M; Bouvier AM; Carrat F; Maynadié M; Beaugerie L; Peyrin-Biroulet L;
Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1324-9. PubMed ID: 24582568
[TBL] [Abstract][Full Text] [Related]
12. Azathioprine and mercaptopurine: lymphoma.
Prescrire Int; 2011 May; 20(116):126. PubMed ID: 21648178
[TBL] [Abstract][Full Text] [Related]
13. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
Caspersen S; Elkjaer M; Riis L; Pedersen N; Mortensen C; Jess T; Sarto P; Hansen TS; Wewer V; Bendtsen F; Moesgaard F; Munkholm P;
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1212-7; quiz 1176. PubMed ID: 18848503
[TBL] [Abstract][Full Text] [Related]
14. Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark.
Pedersen EG; Pottegård A; Hallas J; Friis S; Hansen K; Jensen PE; Gaist D
Eur J Neurol; 2013 Jun; 20(6):942-8. PubMed ID: 23448676
[TBL] [Abstract][Full Text] [Related]
15. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
Peyrin-Biroulet L; Khosrotehrani K; Carrat F; Bouvier AM; Chevaux JB; Simon T; Carbonnel F; Colombel JF; Dupas JL; Godeberge P; Hugot JP; Lémann M; Nahon S; Sabaté JM; Tucat G; Beaugerie L;
Gastroenterology; 2011 Nov; 141(5):1621-28.e1-5. PubMed ID: 21708105
[TBL] [Abstract][Full Text] [Related]
16. Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study.
Nyboe Andersen N; Pasternak B; Friis-Møller N; Andersson M; Jess T
BMJ; 2015 Jun; 350():h2809. PubMed ID: 26048617
[TBL] [Abstract][Full Text] [Related]
17. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
[TBL] [Abstract][Full Text] [Related]
18. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
19. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease.
Gearry RB; Barclay ML; Burt MJ; Collett JA; Chapman BA
Pharmacoepidemiol Drug Saf; 2004 Aug; 13(8):563-7. PubMed ID: 15317038
[TBL] [Abstract][Full Text] [Related]
20. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.
Connell WR; Kamm MA; Dickson M; Balkwill AM; Ritchie JK; Lennard-Jones JE
Lancet; 1994 May; 343(8908):1249-52. PubMed ID: 7910274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
